{"id":"W4410212347","doi":"10.1177/17588359251332154","title":"Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Agricultural Research Institute of Ontario; McMaster University; University of Alberta; University of British Columbia; Ottawa Hospital; University of Ottawa","funders":"Debiopharm","keywords":"Avelumab; Medicine; Lung cancer; Tolerability; Internal medicine; Oncology; Adverse effect; Cancer; Response Evaluation Criteria in Solid Tumors; Nivolumab; Toxicity; Phases of clinical research; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004281517,0.001319587,0.002362366,0.0007802519,0.000444392,0.001208024,0.001334245,0.001263024,0.002188088],"category_scores_gemma":[0.001773809,0.0007180811,0.001638582,0.0007165075,0.001522685,0.001534374,0.0005693801,0.003191988,0.0006658682],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001185239,"about_ca_system_score_gemma":0.001336899,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004698887,"about_ca_topic_score_gemma":0.001029354,"domain_scores_codex":[0.9983406,0.000962128,0.0001051139,0.000232347,0.0001638574,0.000195966],"domain_scores_gemma":[0.9978593,0.0005416811,0.0004990809,0.0003297169,0.0001216296,0.0006485516],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7334986,0.1447907,0.006443913,0.0005903217,0.001028349,0.0001621732,0.0003230075,0.002711053,0.05859023,0.0001807886,0.000721577,0.05095921],"study_design_scores_gemma":[0.1941168,0.7918686,0.007350971,0.00001430075,0.0002573245,0.000126634,0.0000370357,0.0005937983,0.004795017,0.00009320646,0.0007253379,0.00002105362],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996696,0.0007221597,0.0003442858,0.00008073313,0.00003750185,0.001402376,0.0002413708,0.00002584846,0.0004497621],"genre_scores_gemma":[0.9942926,0.0006081603,0.001210118,0.0001825905,0.0001434329,0.001860344,0.0006322063,0.00001743347,0.001053117],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004281517,"threshold_uncertainty_score":0.02264309,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02980140825103593,"score_gpt":0.418773363259961,"score_spread":0.3889719550089251,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}